32 filings
Page 2 of 2
8-K
11o9oudrcu q6jm4
10 Nov 22
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
4:06pm
8-K
aipi0xn
2 Nov 22
Departure of Directors or Certain Officers
4:01pm
8-K
442cu6
30 Sep 22
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
7:48am
8-K
n17ktj6 wx
11 Aug 22
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
5:30pm
8-K
4g1h2r30oc0 o73fnpt
11 Aug 22
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
4:13pm
8-K
y2744d2
5 Jul 22
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035
5:18pm
8-K
j7rw6vdkd268hcv75
13 Jun 22
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
7:16am
8-K
ydceog lf
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
agyztxf
3 Jun 22
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
7:27am
8-K
q4u4714l72w
12 May 22
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
4:14pm
8-K
r44koe l9wq
30 Mar 22
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
8:28pm
8-K
vm7o03v6aqoh ptt1u
11 Jan 22
Amendments to Articles of Incorporation or Bylaws
4:05pm